Profile data is unavailable for this security.
About the company
HilleVax, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing vaccines. The Company's program, HIL-214, is a virus-like particle (VLP) based vaccine candidate in development for the prevention of moderate-to-severe acute gastroenteritis (AGE) caused by norovirus infection. Norovirus is the most common cause of viral AGE worldwide and is characterized by symptoms, including diarrhea, vomiting, abdominal pain, nausea, and, sometimes, fever that may lead to clinically significant dehydration. The Company's HIL-214 is a bivalent (containing two proteins) vaccine candidate consisting of VLPs representing two common genotypes of norovirus and is co-formulated with an aluminum hydroxide (alum) adjuvant, which is commonly used in adult and pediatric vaccines to enhance immunogenicity. HIL-216 includes six common norovirus genotypes, GI.1, GII.2, GII.3, GII.4, GII.6 and GII.17.
- Revenue in USD (TTM)0.00
- Net income in USD-123.57m
- Incorporated2020
- Employees90.00
- LocationHillevax Inc321 Harrison Ave, Suite 500BOSTON 02118United StatesUSA
- Phone+1 (617) 213-5054
- Fax+1 (617) 213-5054
- Websitehttps://www.hillevax.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Zymeworks Inc | 76.01m | -118.67m | 726.85m | 272.00 | -- | 1.57 | -- | 9.56 | -1.74 | -1.74 | 1.10 | 6.57 | 0.1236 | -- | 2.88 | 279,455.90 | -19.30 | -22.58 | -22.01 | -26.90 | -- | -- | -156.13 | -91.17 | -- | -- | 0.0003 | -- | -81.57 | 7.47 | -195.44 | -- | 3.58 | -- |
Exscientia PLC (ADR) | 30.92m | -181.88m | 728.97m | 481.00 | -- | 1.45 | -- | 23.58 | -1.46 | -1.46 | 0.2484 | 3.98 | 0.04 | -- | 2.40 | 64,272.87 | -23.54 | -- | -26.71 | -- | -26.74 | -- | -588.31 | -- | -- | -- | 0.0445 | -- | -0.4971 | -- | -141.17 | -- | -- | -- |
Wave Life Sciences Ltd | 113.31m | -57.51m | 738.60m | 266.00 | -- | 18.16 | -- | 6.52 | -0.5397 | -0.5397 | 1.07 | 0.3987 | 0.5378 | -- | -- | 425,958.70 | -27.30 | -56.98 | -70.41 | -102.38 | -- | -- | -50.76 | -353.20 | -- | -- | 0.00 | -- | 3,005.10 | 51.04 | 64.46 | -- | -35.44 | -- |
OPKO Health Inc | 863.49m | -188.86m | 745.78m | 3.93k | -- | 0.5956 | -- | 0.8637 | -0.2513 | -0.2513 | 1.15 | 1.80 | 0.4133 | 7.80 | 6.89 | 219,718.60 | -9.03 | -7.14 | -10.03 | -8.14 | 36.84 | 34.42 | -21.86 | -13.83 | 1.22 | -15.24 | 0.1574 | -- | -14.01 | -2.70 | 42.49 | -- | -10.19 | -- |
Astria Therapeutics Inc | 0.00 | -72.89m | 746.68m | 59.00 | -- | 3.78 | -- | -- | -2.34 | -2.34 | 0.00 | 5.92 | 0.00 | -- | -- | 0.00 | -30.04 | -64.48 | -31.37 | -68.34 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -40.62 | -- | -- | -- |
enGene Holdings Inc | 0.00 | -106.80m | 751.34m | 33.00 | -- | 6.41 | -- | -- | -4.60 | -4.60 | 0.00 | 2.69 | -- | -- | -- | 0.00 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -1.37 | 0.2653 | -- | -- | -- | -260.87 | -- | -- | -- |
Allogene Therapeutics Inc | 95.00k | -327.27m | 754.15m | 232.00 | -- | 1.47 | -- | 7,938.42 | -2.09 | -2.09 | 0.0006 | 3.04 | 0.0001 | -- | -- | 409.48 | -44.70 | -28.46 | -47.65 | -30.21 | -- | -- | -344,489.50 | -1,123.44 | -- | -- | 0.00 | -- | -39.10 | -- | 3.86 | -- | -14.06 | -- |
Longboard Pharmaceuticals Inc | 0.00 | -54.42m | 755.64m | 50.00 | -- | 12.57 | -- | -- | -2.39 | -2.39 | 0.00 | 1.67 | 0.00 | -- | -- | 0.00 | -89.72 | -- | -105.91 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -23.84 | -- | -- | -- |
Cullinan Oncology Inc | 0.00 | -153.16m | 763.55m | 85.00 | -- | 1.68 | -- | -- | -3.70 | -3.70 | 0.00 | 10.58 | 0.00 | -- | -- | 0.00 | -29.68 | -12.37 | -31.19 | -12.93 | -- | -- | -- | -1,026.78 | -- | -- | 0.00 | -- | -- | -- | -237.72 | -- | -4.44 | -- |
Hillevax Inc | 0.00 | -123.57m | 776.33m | 90.00 | -- | 2.80 | -- | -- | -3.04 | -3.04 | 0.00 | 5.57 | 0.00 | -- | -- | 0.00 | -37.35 | -- | -39.90 | -- | -- | -- | -- | -- | -- | -- | 0.0868 | -- | -- | -- | 22.68 | -- | -- | -- |
Nkarta Inc | 0.00 | -117.50m | 778.07m | 150.00 | -- | 1.99 | -- | -- | -2.40 | -2.40 | 0.00 | 5.56 | 0.00 | -- | -- | 0.00 | -27.59 | -32.39 | -29.14 | -34.05 | -- | -- | -- | -372,519.20 | -- | -- | 0.00 | -- | -- | -- | -3.22 | -- | 106.05 | -- |
Praxis Precision Medicines Inc | 2.45m | -123.28m | 783.71m | 82.00 | -- | 7.47 | -- | 320.27 | -23.64 | -23.64 | 0.3719 | 7.92 | 0.0241 | -- | -- | 29,841.46 | -121.41 | -74.04 | -161.17 | -85.12 | -- | -- | -5,037.88 | -24,589.25 | -- | -- | 0.00 | -- | -- | -- | 42.40 | -- | -4.52 | -- |
Aerovate Therapeutics Inc | 0.00 | -75.52m | 794.09m | 51.00 | -- | 7.23 | -- | -- | -2.87 | -2.87 | 0.00 | 3.94 | 0.00 | -- | -- | 0.00 | -57.49 | -- | -63.65 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -46.61 | -- | -- | -- |
Prime Medicine Inc | 0.00 | -198.13m | 810.79m | 234.00 | -- | 4.95 | -- | -- | -2.17 | -2.17 | 0.00 | 1.37 | 0.00 | -- | -- | 0.00 | -71.51 | -- | -84.13 | -- | -- | -- | -- | -- | -- | -85.97 | 0.00 | -- | -- | -- | -39.52 | -- | -- | -- |
Tango Therapeutics Inc | 36.53m | -101.74m | 821.73m | 140.00 | -- | 3.11 | -- | 22.50 | -1.08 | -1.08 | 0.3865 | 2.48 | 0.0871 | -- | 36.53 | 260,907.10 | -24.25 | -- | -27.59 | -- | -- | -- | -278.54 | -- | -- | -- | 0.00 | -- | 46.93 | -- | 5.95 | -- | -- | -- |
Holder | Shares | % Held |
---|---|---|
Deep Track Capital LPas of 31 Dec 2023 | 2.90m | 5.99% |
Franklin Advisers, Inc.as of 31 Dec 2023 | 1.85m | 3.81% |
BlackRock Fund Advisorsas of 31 Dec 2023 | 1.63m | 3.37% |
T. Rowe Price Investment Management, Inc.as of 31 Dec 2023 | 1.45m | 3.00% |
The Vanguard Group, Inc.as of 31 Dec 2023 | 1.42m | 2.94% |
Citadel Advisors LLCas of 31 Dec 2023 | 724.38k | 1.50% |
Geode Capital Management LLCas of 31 Dec 2023 | 591.15k | 1.22% |
Morgan Stanley & Co. LLCas of 31 Dec 2023 | 453.02k | 0.94% |
SSgA Funds Management, Inc.as of 31 Dec 2023 | 417.25k | 0.86% |
Acuta Capital Partners LLCas of 31 Dec 2023 | 324.60k | 0.67% |